J&J Medical Connect
Oncology
Oncology

Congress Materials - World Conference on Lung Cancer (WCLC 2026)

 

2026 World Conference on Lung Cancer | Sep 12-15 | Seoul, Republic of Korea

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

A Single-Arm Phase II Study of Amivantamab, Lazertinib, and Pemetrexed as First-Line Therapy for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): AMIGO-1 (LACOG 0821)

William Nassib William Junior, Flavio Augusto Da Silva, Ana Caroline Gelatti, Manuela Zereu, Felipe José Silva Melo Cruz, Suellen Nastri Castro, Pedro de Marchi, Eduardo Henrique Cronemberger Costa e Silva, Sulene Cunha Sousa Oliveira, Gilberto de Castro Júnior, Herbert Palmeira, Bruno Cezar de Mendonça Uchôa Júnior, Tatiane Montella, Sabina Bandeira Aleixo, Thais Abreu de Almeida, Luiz Henrique de Lima Araújo, Mariana Seibel, Tainá Cabalheiro, Taiane Rebelatto


This document will be available on Sep 14th 2026

First-Line Amivantamab-Chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall Survival From PAPILLON

Chul Kim, Ke-Jing Tang, Byoung Chul Cho, Luis Paz-Ares, Susanna Cheng, Makoto Nishio, Muthukkumaran Thiagarajan, Jonathan W Goldman, Jen-Yu Hung, Josiane Mourão Dias, Sanjay Popat, Joshua K Sabari, Nicolas Girard, Aaron S Mansfield, Keunchil Park, Rachel E Sanborn, Archan Bhattacharya, Praveen Barala, Mohamed Gamil, Shruti Gandhy, Julie Man, Sujay Shah, Caicun Zhou


This document will be available on Sep 14th 2026

First-Line Subcutaneous Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC: Updated Results From the PALOMA-2 Study

First-Line Subcutaneous Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC: Updated Results From the PALOMA-2 StudyFirst-Line Subcutaneous Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC: Updated Results From the PALOMA-2 Study


This document will be available on Sep 14th 2026

Impact of Common Resistance Mechanisms on Real-World Overall Survival (rwOS) for Patients Receiving Osimertinib

Xiuning Le, Yue Jin, Jin Dai, Levon Demirdjian, Daniel Backenroth, Jiarui Zhang, Joshua C Curtin, Angela Dauti


This document will be available on Sep 13th 2026

IPRO-α Response Rate as a Potential Early Endpoint for Overall Survival in MARIPOSA, a Phase 3 Trial in EGFR-Mutated NSCLC

Benjamin Ackerman, Daniel Backenroth, Ariel Bourla, John Xie, Tao Sun, Sujay Shah, Kiran Patel, Brooke Donohue, Angela Dauti, Levon Demirdjian, Omar F. Khan, Natasha B Leighl, Felipe S Torres, Srinivas Raman, Melissa D Curtis, Felix Baldauf-Lenschen, Alison L Mitro, Thomas J Hennessy, Joel Greshock


This document will be available on Sep 13th 2026

Overall Survival of 2nd-Line Chemotherapy-Containing Regimens After 1st-Line Osimertinib in EGFR-Mutated Advanced NSCLC

Joshua K. Sabari, Lauren Brown, Pratyusha Vadagam, Yin Wan, Alaina Zaki, Andy L. Johnson


This document will be available on Sep 14th 2026

Re-irradiation (ReRT) with NBTXR3 for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I Trial

Saumil N. Gandhi, Enoch Chang, Aileen B. Chen, Stephen G. Chun, Joe Y. Chang, MD, Steven H. Lin, MD, Matthew S. Ning, MD, David Qian, Julianna K. Bronk, Rahul A. Sheth, Jianjun Zhang, Tina Cascone, Marcelo Vailati Negrao, Anne S. Tsao, George R. Blumenschein, Mehmet Altan, John V. Heymach, James W. Welsh, Zhongxing Liao, Roberto F. Casal


This document will be available on Sep 14th 2026

Real-World Characteristics and Treatment Patterns of cEGFRm NSCLC Patients Receiving 2L+ Amivantamab Plus Chemotherapy

Alexander Spira, Ruibin Wang, Cindy Chen, Pratyusha Vadagam, Courtney Morrow, Sanghyuk Seo


This document will be available on Sep 15th 2026

Real-World Treatment Patterns and Outcomes After Osimertinib Progression in EGFR-Mutant NSCLC: A Multi-Center Taiwan Study

Shang-Gin Wu, Kai-Cheng Chang, Yi-Chun Chen, Sheau-Pey Wang, Ji-Fan Hsieh, Hsin-Yi Lin, Hui-Yu Chen, Chih-Hsi Kuo, Jin-Yuan Shih


This document will be available on Sep 15th 2026

Subcutaneous Amivantamab + Lazertinib With Supportive Care in EGFRm NSCLC: Longer Follow-Up Data From the Pragmatic COPERNICUS Study

Balazs Halmos, Janet Tu, Sarah B. Goldberg, Xiuning Le, Narjust Florez, Wade Iams, Kartik Konduri, Danny Nguyen, Luis Raez, Jonathan Riess, Joshua Sabari, David Bjork, Ticiana Leal, Shiven Patel, Annika Hultén, Yichuan Xia, Paul Cifuentes, Farah Shanoon, Illse Leipoldt, Matthew Gumbleton


This document will be available on Sep 15th 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

Would you like to clear and leave your conversation? Message history will be lost.